Related Experiment Videos
Comparing hyperlipidemia control with daily versus twice-weekly simvastatin
Emmanuelle F M Mangin1, Gisela I Robles, William N Jones
1Southern Arizona Veterans Affairs HealthCare System, University of Arizona Center for Health Outcomes & Pharmaco-Economic Research, Tucson, AZ, USA.
The Annals of Pharmacotherapy
|October 14, 2004
Summary
Switching to a twice-weekly simvastatin regimen safely maintained cholesterol goals for most patients. This approach offers potential cost savings and convenience, though further outcome studies are needed.
Area of Science:
- Cardiovascular Medicine
- Pharmacoeconomics
Background:
- Rising costs of statin therapy necessitate exploring cost-effective hyperlipidemia management strategies.
- Hydroxymethylglutaryl coenzyme A reductase inhibitors are crucial for managing hyperlipidemia, but their increasing cost poses a challenge to healthcare systems.
Purpose of the Study:
- To evaluate the effectiveness, safety, cost-effectiveness, and patient satisfaction of transitioning hyperlipidemic patients from daily simvastatin to a twice-weekly regimen.
- Assessing the feasibility of a reduced dosing frequency for simvastatin in managing high cholesterol levels.
Main Methods:
- A 12-week, nonrandomized, open-label study involving patients on daily simvastatin (10 or 20 mg) switched to a higher dose twice weekly (40 or 80 mg, respectively).
- Lipid profiles, including low-density lipoprotein cholesterol (LDL-C), were monitored at baseline, week 6, and week 12.
- Statistical analysis using repeated-measures ANOVA compared lipid levels and determined the proportion of patients achieving LDL-C goals.
Main Results:
- Thirty-one patients completed the study; 68% achieved their LDL-C goal at 12 weeks, similar to baseline (87%), with no statistically significant difference (p=0.068).
- Mean LDL-C levels increased at weeks 6 and 12 compared to baseline (p<0.001), indicating a trend towards reduced efficacy.
- An estimated cost saving of $32,000 per 1000 patients annually was projected, and 55% of patients found the twice-weekly regimen equally or more convenient than daily dosing.
Conclusions:
- A twice-weekly simvastatin regimen appears safe and maintains LDL-C goals for a majority of patients.
- Over half of the patients preferred or found the twice-weekly dosing equally convenient, suggesting improved adherence potential.
- Larger outcome studies are required to validate the long-term efficacy and clinical impact of this less frequent dosing strategy.